BLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
XIAFLEX (collagenase clostridium histolyticum) by Auxilius Pharma is conditions, resulting in lysis of collagen deposits. Approved for peyronie's disease. First approved in 2010.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIAFLEX (collagenase clostridium histolyticum) is an injectable enzyme therapeutic that disrupts collagen deposits through enzymatic lysis. It is indicated for Dupuytren's contracture and Peyronie's disease, both conditions characterized by pathological collagen accumulation. The product utilizes two synergistic collagenases (AUX-I and AUX-II) that selectively target fibrillar collagen types I and III found in disease plaques while sparing structural collagen in arteries, nerves, and large vessels. XIAFLEX offers a minimally invasive enzymatic alternative to surgical intervention for patients with significant contracture or curvature deformity.
$0.1BPart D
Mechanism of Action
conditions, resulting in lysis of collagen deposits. Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord. The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a…
Worked on XIAFLEX at Auxilius Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.